Brekke, Kurt R.; Koenigbauer, Ingrid; Straume, Odd Rune - 2006
the profits are sufficient to cover the entry costs. The other brand-name drug has already lost its patent and faces … profits to the patent-holding firm, making entry of the new drug treatment least likely. Surprisingly, we find that GRP …